Tailored Drug Titration Using Artificial Intelligence
| 대상 질환 | Hypertension |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | Optima Integrated Health |
| 상태 | 완료 |
| 참여자 수 | 165 명 |
| 중재(약물) | optima4BP |
| 시작일 | 2020년 2월 18일 |
| 완료일 | 2022년 12월 30일 |
| 결과 공개일 | 2026년 7월 20일 |
요약
The purpose of the ARTERY Outcomes study is to compare optima-for-blood pressure (optima4BP), a clinical decision support system for hypertension (HTN) treatment optimization to standard of care in patients with essential HTN.
Systolic Blood Pressure [SBP] (mmHg) Measured Remotely [Time Frame: 0 - 6 Months]
| optima4BP | 17.5 ± 5 mmHg |
|---|---|
| Standard of Care (SOC) | 15.1 ± 3.5 mmHg |
| optima4BP | 7.8 ± 0.7 mmHg |
| Standard of Care (SOC) | 5.8 ± 1.1 mmHg |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Community Health Worker Intervention to Address Adverse Pregnancy Outcomes — University of Alabama at Birmingham
- Improving Hypertension Medication Adherence for Older Adults — University of Arizona
- A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Ar — Actelion
- LiveSMART Trial to Prevent Falls in Patients With Cirrhosis — University of Michigan
- SPYRAL HTN-ON MED Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode R — Medtronic Vascular
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontro — AstraZeneca